Dr. Hammers on Study of HyperAcute Renal Immunotherapy in RCC

Hans Hammers, MD, PhD
Published: Thursday, Feb 16, 2017



Hans Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses HyperAcute Renal (HAR) immunotherapy in patients with renal cell carcinoma (RCC).

In a phase I study of alpha-1, 3-galactosyltransferase-expressing allogeneic RCC immunotherapy, patients with metastatic RCC were given injections of HAR for 4 weeks (150 x106 cells/300 x106 cells intradermally). This was followed by 10 weeks of bi-weekly injections.

HAR was well tolerated in this population, says Hammers, and RCC was deemed an appropriate tumor type to target with combination immunotherapy.
 

<<< View more from the 2017 Genitourinary Cancers Symposium



Hans Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses HyperAcute Renal (HAR) immunotherapy in patients with renal cell carcinoma (RCC).

In a phase I study of alpha-1, 3-galactosyltransferase-expressing allogeneic RCC immunotherapy, patients with metastatic RCC were given injections of HAR for 4 weeks (150 x106 cells/300 x106 cells intradermally). This was followed by 10 weeks of bi-weekly injections.

HAR was well tolerated in this population, says Hammers, and RCC was deemed an appropriate tumor type to target with combination immunotherapy.
 

<<< View more from the 2017 Genitourinary Cancers Symposium




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Oncology Briefings™: Overcoming Chronic Iron Overload in Pediatric AML and MDSJun 30, 20181.0
Publication Bottom Border
Border Publication
x